M&A Deal Summary |
|
|---|---|
| Date | 2019-05-16 |
| Target | Realm Therapeutics |
| Sector | Life Science |
| Buyer(s) | ESSA |
| Deal Type | Add-on Acquisition |
| Deal Value | 22M USD |
| Advisor(s) | MTS Health Partners (Financial) Cooley Fasken Martineau DuMoulin (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2009 |
| Sector | Life Science |
| Employees | 25 |
ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA was founded in 2009 and is based in Vancouver, Canada.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
